Medicare Enrolled

Dr. Nicole Bartosh, D.O.

Medical Oncology · Granbury, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
223 S MORGAN ST, Granbury, TX 76048
8177597000
In practice since 2008 (17 years)
NPI: 1326207838 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bartosh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bartosh? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Bartosh

Dr. Nicole Bartosh is a medical oncology in Granbury, TX, with 17 years in practice. Based on federal Medicare data, Dr. Bartosh performed 80,538 Medicare services across 1,553 unique beneficiaries.

Between the years covered by Open Payments, Dr. Bartosh received a total of $1,155 from 22 pharmaceutical and/or device companies across 45 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Bartosh is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice▲ Top 12% volume in TX$ $1,155 industry payments

Medicare Practice Summary

Medicare Utilization ↗
80,538
Medicare services
Top 12% in TX for medical oncology
1,553
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,738 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Injectafer)54,000$1$3
Anti-nausea injection (fosaprepitant)12,000$0$5
Denosumab injection (Prolia/Xgeva)4,380$18$40
Dexamethasone injection (steroid)2,957$0$5
Anti-nausea injection (Aloxi/palonosetron)1,140$1$52
Injection, granisetron hydrochloride, 100 mcg900$0$10
Office visit, established patient (30-39 min)700$89$275
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less522$22$100
COVID-19 test, self-administered506$12$30
Office visit, established patient, complex (40-54 min)404$134$350
Injection of additional new drug or substance into vein387$12$70
Administration of chemotherapy into vein, 1 hour or less365$97$412
Drug injection, under skin or into muscle275$10$60
Administration of chemotherapy into vein, each additional hour230$21$93
Injection, diphenhydramine hcl, up to 50 mg228$1$10
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less161$46$190
Injection, zoledronic acid, 1 mg153$7$300
Administration of additional new drug or substance into vein, 1 hour or less145$49$202
Office visit, established patient (20-29 min)139$58$175
Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month138$47$160
Piflufolastat f-18, diagnostic, 1 millicurie118$458$1,409
Comprehensive metabolic blood panel99$10$50
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour87$15$60
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg71$1$5
Nuclear medicine study from skull base to mid-thigh with ct scan62$1,150$4,069
Ct scan of chest with contrast48$53$401
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries47$106$450
New patient office visit, complex (60-74 min)43$166$497
Collection of blood sample from implanted device39$20$60
Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month38$36$120
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle34$25$105
New patient office visit (45-59 min)33$127$400
CT scan of abdomen and pelvis with contrast31$159$681
Chronic care management, first 20 min/month24$48$161
Injection of drug or substance into vein19$28$145
Advance care planning consultation, first 30 min15$63$250
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
68.0% high complexity
28.9% medium
3.1% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$1,155
Total received (2018-2024)
Avg $165/year across 7 years
Bottom 31% in TX for medical oncology
22
Companies
45
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,104 (95.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$52 (4.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$34
2023
$25
2022
$14
2021
$189
2020
$179
2019
$284
2018
$430

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Lilly USA, LLC
$165
Astellas Pharma US Inc
$138
PUMA BIOTECHNOLOGY, INC.
$136
Sirtex Medical Inc
$112
Puma Biotechnology, Inc.
$112
PFIZER INC.
$76
GENZYME CORPORATION
$51
Takeda Pharmaceuticals U.S.A., Inc.
$49
Janssen Biotech, Inc.
$49
Acrotech Biopharma LLC
$40
Novartis Pharmaceuticals Corporation
$35
Verastem, Inc.
$34
Pharmacyclics LLC, An AbbVie Company
$25
Incyte Corporation
$23
AstraZeneca Pharmaceuticals LP
$20
BOSTON SCIENTIFIC CORPORATION
$17
Genentech USA, Inc.
$15
GlaxoSmithKline, LLC.
$14
TerSera Therapeutics LLC
$13
SANOFI-AVENTIS U.S. LLC
$12
Gilead Sciences, Inc.
$12
Heron Therapeutics, Inc.
$9
Top 3 companies account for 38.0% of total payments
Associated products mentioned in payments ›
ALIMTA · BELEODAQ · BOSULIF · CINVANTI · CYRAMZA · Copiktra · DARZALEX · Erleada · GAZYVA · IBRANCE · IMBRUVICA · JAKAFI · JEVTANA · LYNPARZA · MEKINIST · NERLYNX · Nerlynx · OJJAARA · PROMACTA · RETEVMO · ROTAGLIDE · SIR-Spheres Microspheres · SUTENT · VERZENIO · Vyloy · XALKORI · XTANDI · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $1 per 100 Medicare services performed
Looking for a medical oncology in Granbury?
Compare medical oncologys in the Granbury area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
1
Per 100K population
1.6
County median income
$86,802
Nearest hospital
LAKE GRANBURY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Bartosh is a mixed practice specialist, with above-average Medicare volume (top 12% in TX), and low-engagement industry engagement, with 17 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Bartosh experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Bartosh performed 54,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bartosh receive payments from pharmaceutical companies?
Yes. Dr. Bartosh received a total of $1,155 from 22 companies across 45 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bartosh's costs compare to other medical oncologys in Granbury?
Dr. Bartosh's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bartosh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →